Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (2022 - 2025)

Stoke Therapeutics has reported Shares Outstanding over the past 4 years, most recently at $58.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $58.9 million for Q4 2025, up 9.05% from a year ago — trailing twelve months through Dec 2025 was $58.9 million (up 9.05% YoY), and the annual figure for FY2025 was $58.9 million, up 9.05%.
  • Shares Outstanding for Q4 2025 was $58.9 million at Stoke Therapeutics, up from $55.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for STOK hit a ceiling of $58.9 million in Q4 2025 and a floor of $39.0 million in Q1 2022.
  • Median Shares Outstanding over the past 4 years was $46.2 million (2023), compared with a mean of $47.8 million.
  • Biggest five-year swings in Shares Outstanding: rose 19.52% in 2024 and later rose 4.12% in 2025.
  • Stoke Therapeutics' Shares Outstanding stood at $39.4 million in 2022, then grew by 16.43% to $45.9 million in 2023, then increased by 17.67% to $54.0 million in 2024, then grew by 9.05% to $58.9 million in 2025.
  • The last three reported values for Shares Outstanding were $58.9 million (Q4 2025), $55.1 million (Q3 2025), and $54.7 million (Q2 2025) per Business Quant data.